Merck is granted rights to Xencor's monoclonal antibody patent

07/3/2013 | Genetic Engineering & Biotechnology News

Merck & Co. secured nonexclusive licensing rights to one of Xencor's engineering patents for a monoclonal antibody. The deal allows Merck to use the patent for an undisclosed product and gives it an option to license the same patent for future products. Xencor is entitled to an upfront payment, yearly maintenance fees and potential milestone payments and sales royalties.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX